Follow us:

Microsoft Pri0

Welcome to Microsoft Pri0: That's Microspeak for top priority, and that's the news and observations you'll find here from Seattle Times technology reporter Matt Day.

Category: Biotechnology
January 7, 2008 at 6:29 PM

A beehive of biotech action in SF

Reporter Angel Gonzalez poses this question from San Francisco: What happens when you cram nearly 8,000 biotech executives, investors, venture capitalists and analysts into the narrow, gilded corridors of the Westin hotel on San Francisco’s Union Square? The JP Morgan Healthcare Conference, one of the life sciences sector’s most important pow-wows. The ambience is that of a…

More

Comments | More in Biotechnology

November 7, 2007 at 5:18 PM

Potential rival to Enbrel on the horizon

An experimental arthritis therapy known as golimumab showed promising results in a late-stage clinical study for the treatment of psoriatic arthritis, Johnson & Johnson unit Centocor and Schering-Plough said Wednesday. The data signals the potential appearance of a new rival to Enbrel, the best-selling treatment developed in Seattle by Immunex and now sold by…

More

Comments | More in Biotechnology

November 5, 2007 at 5:48 PM

Pro-Provenge group rides the bus

After placing an ad in the Washington Post and staging rallies in front of the Capitol and the FDA’s headquarters, activists angry at the agency’s decision to withhold approval for the prostate cancer drug Provenge have found a new way to voice their discontent. Starting today, 25 Washington Metropolitan Area Transit buses will carry an…

More

Comments | More in Biotechnology

November 2, 2007 at 6:42 PM

Life Sciences Discovery Fund money draws 75 applications

Tobacco money has a lot of friends. The Life Sciences Discovery Fund — an institution charged by the state to distribute the funds from the tobacco settlement — said today that 75 Washington research programs are bidding for grants. Applicants include hospitals, universities and research institutions, as well as collaborations between companies and non-profits. Proposals include vaccines,…

More

Comments | More in Biotechnology

October 31, 2007 at 4:29 PM

Mystery Gorilla strikes again at ZymoGenetics

Forget the intricacies of molecular biology — the most elusive mystery to haunt Seattle’s largest independent biotech company is the true identity of the gorilla that has appeared every Halloween afternoon for at least 15 years. On Wednesday, the gorilla struck again, wading through the company’s fancy Eastlake headquarters and aggressively pushing candy at the employees,…

More

Comments | More in Biotechnology

October 30, 2007 at 5:24 PM

Nastech slips on Wall Street

Nastech Pharmaceuticals had a rough time in the market Tuesday in the wake of its most recent quarterly earnings report. Shares fell 13.27 percent to $12.88 as the Bothell firm – which specializes in delivering therapies through its proprietary nasal spray technology – saw its quarterly loss more than double to $16.4 million. Profits are not as…

More

Comments | More in Biotechnology

September 18, 2007 at 12:59 PM

Gates Foundation executive is knighted

Dr. Tadataka “Tachi” Yamada, president of the global health program at the Bill & Melinda Gates Foundation, today can add knighthood to his list of achievements. RICHARD BROWN/GATES FOUNDATION Tachi Yamada joined the Gates Foundation in 2006. Yamada received the honor for his work at pharmaceutical giant GlaxoSmithKline, where he was head of research and development from…

More

Comments | More in Biotechnology, Personalities, Philanthropy

Next Page »